Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Neuralink's N1 chip trial in Canada show positive results by end of 2025?
Yes • 50%
No • 50%
Peer-reviewed journal publications or official Neuralink announcements
Neuralink Approved for First Clinical Trial in Canada Using N1 Chip for ALS and SCI Patients
Nov 20, 2024, 07:51 PM
Neuralink has received approval from Health Canada to initiate recruitment for its first clinical trial in Canada, aimed at individuals with quadriplegia due to ALS or spinal cord injury (SCI). The trial will utilize Neuralink's N1 chip, which enables paralyzed individuals to control devices such as computers through brain-computer interface (BCI) technology. This advancement is expected to have a transformative impact on the lives of many. Interested participants can find more information and apply through Neuralink's Patient Registry.
View original story
Yes • 50%
No • 50%
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Yes • 50%
No • 50%
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Collaboration with a Canadian university • 25%
No major partnership • 25%
Partnership with a tech company • 25%
Partnership with a Canadian healthcare provider • 25%
Initial results published • 25%
Trial discontinued • 25%
Recruitment completion • 25%
Trial expansion approved • 25%